Jean Boulle Group Company VDyne Receives FDA Approval to Initiate Pivotal Trial
1st April 2026 The Jean Boulle Group is pleased to note the announcement made by Medtech device company VDyne (“the Company”) that the U.S. Food & Drug Administration (“FDA”) has approved an investigational device exemption (IDE) for the Company’s pivotal clinical trial evaluating its Transcatheter Tricuspid Valve Replacement (TTVR) system. The IDE approval enables the start…
